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Abstract 
 
Neuropeptide Y, Y1 receptors are found in neuronal as well as bone tissue and Y1 signalling 
has been implicated in the regulation of bone mass. However, the contribution of Y1 
receptors located in these different tissues, particularly that of the bone-specific Y1 receptors, 
to the regulation of bone homeostasis is unclear. Here we demonstrate that osteoblast-
specific Y1 receptor deletion resulted in a marked increase in femoral cancellous bone 
volume, trabecular thickness and trabecular number. This is the result of elevated osteoblast 
activity as shown by increased mineral apposition rate and bone formation rate, and is 
associated with an upregulation in the mRNA expression levels of alkaline phosphatase, 
osteocalcin and dentin matrix protein-1. Furthermore, osteoblastic Y1 receptor deletion also 
led to increased mineral apposition rate on both the endocortical and the periosteal surfaces 
resulting in increased femoral diameter. Together these data demonstrate a direct role for the 
Y1 receptor on osteoblasts in the regulation of osteoblast activity and bone formation in vivo 
and suggest that targeting Y1 receptor signalling directly in the bone may have potential 
therapeutic implications for stimulating bone accrual in diseases such as osteoporosis. 
 
Introduction 
 
Osteoporosis is an increasingly common and debilitating condition creating major social and 
economic burdens worldwide. Whilst antiresorptive treatments can be successful in 
preventing progression of the condition, there is a pressing need for the development of 
effective anabolic agents capable of rebuilding the bone that has already been lost. This is 
particularly so in light of the fact that by the time osteoporosis is diagnosed as a result of 
fracture, considerable bone loss has usually already occurred [1] and [2]. A potential target for 
the development of bone anabolic agents is the neuropeptide Y (NPY) system, notably Y1 
and Y2 receptors, which has been revealed as a powerful pathway in the control of bone 
mass through the regulation of osteoblast activity. Germline deletion of either Y1 or Y2 
receptors in mice leads to a high bone mass phenotype associated with enhanced osteoblast 
activity [3] and [4]. Y2 receptors are predominantly expressed in the central nervous system 
where they are usually pre-synaptic [5] and [6]. Consistent with a central role of Y2 receptors 
in the regulation of bone, it has clearly been shown that the deletion of hypothalamic Y2 
receptors is sufficient to replicate the high bone mass phenotype observed in germline Y2 
receptor knockout (Y2−/−) mice [4]. In contrast, hypothalamic deletion of Y1 receptors did not 
alter bone homeostasis [3], suggesting that non-hypothalamic Y1 receptors are important for 
the control of bone. Indeed, recent in vitro studies suggest that the Y1 receptor plays a 
peripheral, osteoblastic role in the regulation of bone formation [7]. 
 Despite being first characterised as a post-synaptic receptor, the Y1 receptor can 
also be found pre-synaptically and has a wide distribution both in the central nervous system 
as well as in the periphery [8] and [9]. Germline Y1 receptor knockout (Y1−/−) mice have a 
high bone mass phenotype with a generalised increase in bone formation on both cortical and 
cancellous surfaces [3]. In addition, osteoclast surface was increased, suggesting that bone 
resorption may also be elevated in these mice [3]. The deletion of both Y1 and Y2 receptors 
did not lead to an additive effect on bone thus suggesting that they may be acting at different 
points along the same pathway [3]. Y1 receptor, but not Y2 receptor, expression has been 
demonstrated by in-situ hybridisation in osteoblastic cells lining both cortical and trabecular 
bone surfaces [10], and by reverse transcription PCR in calvaria and long bone [11]. 
Moreover, we have recently shown that the Y1 receptor directly inhibits the differentiation of 
mesenchymal progenitor cells as well as the activity of mature osteoblasts in vitro [7]. 
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Furthermore, identification of NPY expression in osteoblasts [12] and osteocytes [11] 
suggests the potential for local control of osteoblast activity by NPY via Y1 receptors. Indeed, 
the treatment of mouse calvarial osteoblasts with exogenous NPY resulted in an inhibition of 
osteoblast activity [11]. 
 Given the clear expression of Y1 receptor mRNA in osteoblasts [10] combined with 
the increased mineral formation by Y1-deficient osteoblasts in vitro [7], we hypothesise that 
osteoblastic Y1 receptors play a direct regulatory role in bone metabolism. Therefore, we 
generated mice with selective deletion of the Y1 receptor in osteoblasts (Y1lox/lox;Cre/+) by 
crossing Y1lox/lox mice with mice expressing Cre specifically in maturing osteoblasts under the 
control of a 2.3 kb fragment of the α1(I)-collagen promotor [13]. Investigating the in vivo bone 
phenotype of these Y1lox/lox;Cre/+ mice allows us to determine the role of direct signalling via 
osteoblastic Y1 receptors on bone mass. 
 
Materials and methods 
 
Mice 
 All animal experiments were approved by the Garvan Institute/St Vincent's Hospital 
Animal Experimentation Ethics Committee and conducted in accordance with relevant 
guidelines and regulations. 
 Mice with osteoblast-specific deletion of the Y1 receptor (Y1lox/lox;Cre/+) were generated 
as previously described [7] by mating mice expressing Cre under the control of a 2.3 kb 
fragment of the rat α1(I)-collagen promoter with Y1lox/lox mice. Cre-mediated recombination 
resulted in osteoblast-specific deletion of the entire coding region of the Y1 gene. Male 
Y1lox/lox;Cre/+ mice were bred with female Y1lox/lox mice to generate both Y1lox/lox;Cre/+ mice and 
Y1lox/lox littermates to be used as controls. Genotypes were determined by PCR as previously 
described [7]. Male mice were used for all experiments reported here, at 16 weeks of age, an 
age where it is known that cancellous bone volume is at its peak before declining with age, 
and the mice were maintained on a mixed C57/BL6-129/SvJ background. 
 
Tissue collection 
 Male Y1lox/lox;Cre/+ and Y1lox/lox mice were injected with the fluorescent compound 
calcein (15 mg/kg; Sigma-Aldrich, St Louis, MO, USA) 3 and 10 days prior to tissue collection 
to enable subsequent calculation of bone formation rate. Whole body lean mass, fat mass, 
bone mineral content (BMC) and bone mineral density (BMD) were measured in mice 
anesthetised with isoflurane using a dedicated mouse dual X-ray absorptiometry (DXA) 
(Lunar Piximus II, GE Medical Systems, Madison WI) 3 days prior to tissue collection. BMD 
and BMC were also measured for the lumbar vertebrae with a sample area 75 pixels in length 
proximal from the lower lumbar. At 16 weeks of age, mice were culled between 13.00 and 
16.00 hours by cervical dislocation and decapitation for collection of trunk blood. Serum was 
separated, immediately frozen and stored at −20 °C. Brains were immediately frozen on dry 
ice and stored at −80 °C. The white adipose tissue (WAT) depots (right side inguinal, 
retroperitoneal, epididymal (gonadal) and mesenteric), and skeletal muscle were removed, 
weighed, frozen on dry ice and stored at −80 °C. Femurs, tibias and caudal vertebrae were 
excised, fixed overnight in 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) at 
4 °C and then stored in 70% ethanol at 4 °C before undergoing processing. 
 
Plasma assays 
 Serum glucose was measured using a glucose oxidase assay kit (Trace Scientific, 
Clayton, Victoria, Australia) and serum insulin was measured using an ELISA kit from Linco 
Research (St Charles, Missouri, USA). Serum corticosterone was measured using a 
radioimmunoassay detection kit from MP Biomedicals (Irvine, CA, USA), whilst serum insulin 
like growth factor (IGF)-1 was measured using a radioimmunoassay detection kit from 
Bioclone (Sydney, NSW, Australia). 
 
Reverse-transcription PCR 
 Bone marrow stromal cells (BMSCs) were isolated, cultured and differentiated as 
previously described [7]. BMSCs cultured for 10 days in osteogenic media were used for RNA 
extractions. All RNA extractions on BMSCs and frozen tissue were carried out using TRIzol® 
reagent (Sigma) according to the manufacturer's instructions and reverse transcription-PCR 
was performed as previously described [7]. PCR reactions were performed for the number of 
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cycles indicated with denaturing at 94 °C and extension at 72 °C. Mouse glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a housekeeping gene to control for 
variations between samples. The specific primers and annealing temperatures used along 
with the resultant product sizes obtained are as detailed previously [10] and as follows for 
Cre: 300 bp, 55 °C, forward: 5′-GTTTCACTGGTTATGCGG-3′, reverse: 5'-AAGTGCCTTCTC- 
TACACC-3′. 
 
Quantitative real time-PCR 
 RNA was extracted from the mid-shaft of femurs and tibias isolated from 7- to 9-
week-old male mice, snap frozen in liquid nitrogen and homogenised in 2 mL TRIzol® 
reagent using a Polytron homogeniser. All RNA extractions were performed by using TRIzol® 
reagent according to the manufacturer's instructions. RNA samples were subsequently 
checked for consistent quality and quantified using the Agilent 2100 Bioanalyser (Agilent 
Technologies) according to the manufacturer's instructions. 1 µg of total RNA was taken for 
cDNA synthesis with oligo(dT)20 and random hexamers using the SuperScript III First-Strand 
Synthesis System for reverse transcription-PCR (Invitrogen). Quantitative real-time PCR for 
Runx2, Osterix, alkaline phosphatase, osteocalcin and DMP-1 was then carried out using the 
TaqMan© Universal PCR master mix, ABI Prism 7900 HT Sequence Detection System and 
inventoried kits containing primers and probes (all from Applied Biosystems). Quantitative 
real-time PCR for RANK-ligand and OPG was carried out using the Lightcycler 480 Probes 
Mastermix with Universal Probe Library (UPL) probes (all from Roche) and the following 
primers: RANK-ligand forward: 5′-tgaagacacactacctgactcctg-3′, reverse: 5′-
ccacaatgtgttgcagttcc-3′; OPG forward: 5′-ccacgcaaaagtgtggaata-3′, reverse: 5′-
ggcaaactgtccaccaaaa-3′. To control for variability in amplification due to differences in starting 
mRNA concentrations, β-actin was used as an internal standard. The relative expression of 
target mRNA was computed from the target Ct values and the β-actin Ct value using the 
standard curve method (Applied Biosystems). 
 
Bone histomorphometry 
 Bone histomorphometry was carried out on 5 µm sagittal sections of the distal half of 
the right femur as previously described [14]. Briefly, sections were stained for mineralised 
bone and trabecular bone volume, trabecular thickness and trabecular number were 
calculated. In addition, fluorescence microscopy was used to calculate mineral apposition 
rate, mineralising surface and bone formation rate whilst osteoclast surface and osteoclast 
number were estimated using tartrate-resistant acid phosphatase-stained sections. Cortical 
mineral apposition rate was measured in an endosteal and a periosteal region both extending 
1000 µm distal from the mid-point, as previously described [14]. 
 
Bone micro-computed tomography (micro-CT) 
 Following fixation, left femora were cleaned of muscle and analyses of the cortical 
bone were carried out using micro computed tomography (micro-CT) with a Skyscan 1174 
scanner and associated analysis software (Skyscan, Aartselaar, Belgium) as previously 
described [15]. Briefly, analyses of the cortical bone were carried out in 150 slices (1.07 mm) 
selected 750 slices (5.37 mm) proximally from the distal growth plate resulting in calculations 
of the following parameters: total tissue area, bone area, marrow area, endosteal perimeter, 
periosteal perimeter, cortical thickness, and polar moment of inertia (an index of strength). 
 
Statistical analyses 
 All data are expressed as means ± SEM. Differences between knockout and wildtype 
mice were assessed by ANOVA. Statistical analyses were performed with SPSS for Mac OS 
X, version 17.0 (SPSS Inc., Chicago, IL, USA). For all statistical analyses, p < 0.05 was 
accepted as being statistically significant, with p < 0.1 accepted as showing a trend of 
change. 
 
Results 
 
Y1 receptor deletion is restricted to osteoblasts 
 The restriction of Y1 receptor deletion solely to osteoblastic cells of Y1lox/lox;Cre/+ mice was 
confirmed by RT-PCR for Cre and Y1 receptor expression on RNA isolated from several 
tissues from Y1lox/lox and Y1lox/lox;Cre/+ mice. As shown in Fig. 1, in Y1lox/lox;Cre/+ mice which carry 
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the Cre transgene, Cre mRNA expression was indeed restricted to bone tissue and isolated 
BMSCs and was not observed in other tissues examined namely brain, muscle or epididymal 
white adipose tissue. No Cre mRNA expression was observed in any tissue investigated from 
Y1lox/lox littermates. In addition, coincident with Cre expression, Y1 receptor expression was 
down-regulated in bone tissue and cultured BMSCs derived from Y1lox/lox;Cre/+ mice (Fig. 1). 
Indeed, quantification of multiple analyses by densitometry revealed a 95% reduction in Y1 
receptor expression in bone tissue from Y1lox/lox;Cre/+ mice compared to their wildtype 
littermates. Y1 receptor expression was unaffected in other tissues examined, confirming the 
generation of mice with the Y1 receptor deleted solely in osteoblasts. 
	  	   	  
 
Osteoblast-specific Y1 receptor deletion enhances bone formation with no effect on adiposity 
 In addition to high bone mass, germline Y1−/− mice are characterised by increased 
adiposity and hyperinsulinemia, an obese phenotype that is exacerbated with advancing age 
[3], [16] and [17]. Therefore, to examine whether osteoblast-specific deletion of the Y1 
receptor could recapitulate the high bone mass phenotype of germline Y1−/− mice 
independent of other metabolic changes, we first measured body composition by DXA in 
Y1lox/lox and Y1lox/lox;Cre/+ mice at 16 weeks of age, a similar age to that previously used for the 
analysis of the bone phenotype in germline Y1−/− mice [3] and [10]. Importantly, no differences 
were observed between Y1lox/lox and Y1lox/lox;Cre/+ mice with respect to body weight, whole body 
lean tissue mass or fat mass (Table 1). Similar stature and adiposity between Y1lox/lox;Cre/+ and 
Y1lox/lox mice was further confirmed by a lack of difference in femur length and the weight of 
individual white adipose tissue depots (Table 1 and data not shown). In addition, we found no 
significant effect of genotype on serum concentrations of insulin, glucose, corticosterone, or 
IGF-1 (Table 1). Importantly, however, whole body DXA analysis revealed a trend towards 
increased BMC and BMD in the Y1lox/lox;Cre mice compared to their wildtype littermates with a 
significant increase in BMC also evident at the lumbar vertebrae (Table 1), consistent with a 
role for Y1 receptors on osteoblasts in the inhibition of bone formation independently of any 
effects on adiposity or hormones such as corticosterone or IGF-1. Therefore, in order to 
further investigate the bone phenotype of these mice, we measured cancellous and cortical 
bone parameters by histomorphometry and micro computed tomography (micro-CT) in distal 
femurs isolated from 16 week old Y1lox/lox;Cre/+ mice, as compared to their Y1lox/lox littermates. 
 
 	  
tomography (micro-CT) with a Skyscan 1174 scanner and associated
analysis software (Skyscan, Aartselaar, Belgium) as previously
described [15]. Brieﬂy, analyses of the cortical bone were carried out
in 150 slices (1.07 mm) selected 750 slices (5.37 mm) proximally
from the distal growth plate resulting in calculations of the following
parameters: total tissue area, bone area, marrow area, endosteal
perimeter, periosteal perimeter, cortical thickness, and polar moment
of inertia (an index of strength).
Statistical analyses
All data are expressed as means±SEM. Differences between
knockout and wildtype mice were assessed by ANOVA. Statistical
analyses were performed with SPSS for Mac OS X, version 17.0 (SPSS
Inc., Chicago, IL, USA). For all statistical analyses, pb0.05 was accepted
as being statistically signiﬁcant, with pb0.1 accepted as showing a
trend of change.
Results
Y1 receptor deletion is restricted to osteoblasts
The restriction of Y1 receptor deletion solely to osteoblastic cells of
Y1lox/lox;Cre/+ mice was conﬁrmed by RT-PCR for Cre and Y1 receptor
expression on RNA isolated from several tissues from Y1lox/lox
and Y1lox/lox;Cre/+ mice. As shown in Fig. 1, in Y1lox/lox;Cre/+ mice
which carry the Cre transgene, Cre mRNA expression was indeed
restricted to bone tissue and isolated BMSCs and was not observed in
other tissues examined namely brain, muscle or epididymal white
adipose tissue. No Cre mRNA expression was observed in any tissue
investigated from Y1lox/lox littermates. In addition, coincident with Cre
expression, Y1 receptor expressionwas down-regulated in bone tissue
and cultured BMSCs derived from Y1lox/lox;Cre/+ mice (Fig. 1). Indeed,
quantiﬁcation of multiple analyses by densitometry revealed a 95%
reduction in Y1 receptor expression in bone tissue from Y1lox/lox;Cre/+
mice compared to their wildtype littermates. Y1 receptor expression
was unaffected in other tissues examined, conﬁrming the generation
of mice with the Y1 receptor deleted solely in osteoblasts.
Osteoblast-speciﬁc Y1 receptor deletion enhances bone formation with
no effect on adiposity
In addition to hig bone mass, germline Y1−/− mice are
characterised by increased adiposity and hyp rinsulinemia, an obese
phenotype that is exacerbated with advancing age [3,16,17]. There-
fore, to examine whether osteoblast-speciﬁc deletion of the Y1
receptor could recapitulate the high bonemass phenotype of germline
Y1−/− mice ind pendent of oth r metabolic changes, we ﬁ st
measured body composition by DXA in Y1lox/lox and Y1lox/lox;Cre/+
mice at 16 weeks of age, a similar age to that previously used for the
analysis of the bone phenotype in germline Y1−/− mice [3,10].
Importantly, no differences were observed between Y1lox/lox and
Y1lox/lox;Cre/+ mice with respect to body weight, whole body lean
tissue mass or fat mass (Table 1). Similar stature and adiposity
between Y1lox/lox;Cre/+ and Y1lox/lox mice was further conﬁrmed by a
lack of difference in femur length and the weight of individual white
adipose tissue depots (Table 1 and data not shown). In addition, we
found no signiﬁcant effect of genotype on serum concentrations of
insulin, glucose, corticosterone, or IGF-1 (Table 1). Importantly,
however, whole body DXA analysis revealed a trend towards
increased BMC and BMD in the Y1lox/lox;Cre mice compared to their
wildtype littermates with a signiﬁcant increase in BMC also evident at
the lumbar vertebrae (Table 1), consistent with a role for Y1 receptors
on osteoblasts in the inhibition of bone formation independently of
any effects on adiposity or hormones such as corticosterone or IGF-1.
Therefore, in order to further investigate the bone phenotype of these
mice, we measured cancellous and cortical bone parameters by
histomorphometry and micro computed tomography (micro-CT)
in distal femurs isolated from 16 week old Y1lox/lox;Cre/+ mice, as
compared to their Y1lox/lox littermates.
Cancellous bone
Histomorphometric analysis revealed that male Y1lox/lox;Cre/+mice
have signiﬁcantly greater (by 40%) cancellous bone volume in the
distal femoral metaphysis compared to their wildtype littermates
with signiﬁcantly greater trabecular thickness and trabecular number
(Fig. 2A–D). Similar to male germline Y1−/− mice [3], this was
associated with an increase in osteoblast activity as shown by
signiﬁcantly enhanced MAR (Fig. 2E) and bone formation rate
(Fig. 2F), without a change in the extent of bone undergoing bone
formation (mineralising surface (Fig. 2G)). However, in contrast to
germline Y1−/− mice, the activity of the osteoclastic lineage was
similar between Y1lox/lox;Cre/+ mice and their wildtype littermates in
that therewas no difference observed in osteoclast surface (Fig. 2H) or
osteoclast number (Fig. 2I). Therefore, the enhanced cancellous
bone volume observed in Y1lox/lox;Cre/+ mice is entirely associated
with enhanced bone formation with no change in bone resorption
parameters.
Cortical bone
Micro-CT was used to examine the effect of osteoblast-speciﬁc Y1
receptor deletion on cortical bone. At the mid-femur, Y1lox/lox;Cre/+
mice displayed a generalised increase in the diameter of the femur as
shown by signiﬁcant increases in total tissue area, marrow area,
periosteal perimeter and endosteal perimeter (Fig. 3A–D). Despite
Fig. 1. Osteoblast-speciﬁc Y1 receptor deletion. Y1 receptor knockdown and Cre
expression in bone tissue and BMSCs after 10 days in culture in osteogenicmedia but not
in brain, muscle or epididymal white adipose tissue (WATe) derived from Y1lox/lox;Cre/+
mice but not Y1lox/lox littermates. Data show results for PCR performed with (+) and
without (−) reverse transcription. PCRwas performed for 22–26 cycles for GAPDH, 32–
26 cycles for Y1 receptor, and 36–40 cycles for Cre varying between tissue types but
consistent across genotypes.
Table 1
Body composition, serum parameters and bone densitometry of Y1lox/lox;Cre/+ mice.
Y1lox/lox Y1lox/lox;Cre/+
Body weight (g) 26.47±0.50 26.77±0.66
Lean mass (g) 20.55±0.29 20.52±0.45
Fat mass (g) 4.70±0.29 4.54±0.27
Femur length (mm) 15.99±0.12 15.94±0.14
Insulin (pM) 136.24±29.88 165.90±35.97
Glucose (mM) 10.95±0.43 11.79±0.49
Corticosterone (ng/mL) 89.42±21.89 119.26±23.08
IGF-1 (ng/mL) 215.34±20.98 230.09±16.70
Whole body BMC (g) 0.322±0.006 0.341±0.009 c
Whole body BMD (g/cm2) 0.0500±0.0006 0.0519±0.0008 b
Lumbar BMC (g) 0.0285±0.0005 0.0315±0.0013 a
Lumbar BMD (g/cm2) 0.0513±0.0007 0.0528±0.0020
Means±SEM of 9–13 male mice per group shown.
a pb0.05.
b p=0.06.
c p=0.09 compared to Y1lox/lox mice.
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Cancellous bone 
 Histomorphometric analysis revealed that male Y1lox/lox;Cre/+ mice have significantly 
greater (by 40%) cancellous bone volume in the distal femoral metaphysis compared to their 
wildtype littermates with significantly greater trabecular thickness and trabecular number (Fig. 
2A–D). Similar to male germline Y1−/− mice [3], this was associated with an increase in 
osteoblast activity as shown by significantly enhanced MAR (Fig. 2E) and bone formation rate 
(Fig. 2F), without a change in the extent of bone undergoing bone formation (mineralising 
surface (Fig. 2G)). However, in contrast to germline Y1−/− mice, the activity of the osteoclastic 
lineage was similar between Y1lox/lox;Cre/+ mice and their wildtype littermates in that there was 
no difference observed in osteoclast surface (Fig. 2H) or osteoclast number (Fig. 2I). 
Therefore, the enhanced cancellous bone volume observed in Y1lox/lox;Cre/+ mice is entirely 
associated with enhanced bone formation with no change in bone resorption parameters. 
 
Cortical bone 
 Micro-CT was used to examine the effect of osteoblast-specific Y1 receptor deletion 
on cortical bone. At the mid-femur, Y1lox/lox;Cre/+ mice displayed a generalised increase in the 
diameter of the femur as shown by significant increases in total tissue area, marrow area, 
periosteal perimeter and endosteal perimeter (Fig. 3A–D). Despite no significant changes in 
cortical bone area or cortical thickness (Fig. 3E–F), the greater femur size in Y1lox/lox;Cre/+ mice 
(Fig. 3G) was associated with increased polar moment of inertia, an index of bone strength 
(Fig. 3H). 
 To investigate the cellular basis for these differences, MAR on the endocortical and 
periosteal surfaces were examined. Interestingly, endocortical MAR was significantly elevated 
by approximately 60% in male Y1lox/lox;Cre/+ mice compared to their wildtype littermates 
(Fig. 3I). Cortical osteoblast activity was also elevated on the periosteal surface as shown by 
a significant increase in periosteal MAR in the absence of osteoblastic Y1 receptors (Fig. 3J). 
 Together these data demonstrate that specific deletion of osteoblastic Y1 receptors 
enhances osteoblast activity leading to increases in both cortical and cancellous bone mass, 
with no effect on bone resorption, adiposity, circulating concentrations of the hormones 
insulin, IGF-1 or corticosterone, or body weight. 
tomography (micro-CT) with a Skyscan 1174 scanner and associated
analysis software (Skyscan, Aartselaar, Belgium) as previously
described [15]. Brieﬂy, analyses of the cortical bone were carried out
in 150 slices (1.07 mm) selected 750 slices (5.37 mm) proximally
from the distal growth plate resulting in calculations of the following
parameters: total tissue area, bone area, marrow area, endosteal
perimeter, periosteal perimeter, cortical thickness, and polar moment
of inertia (an index of strength).
Statistical analyses
All data are expressed as means±SEM. Differences between
knockout and wildtype mice were assessed by ANOVA. Statistical
analyses were performed with SPSS for Mac OS X, version 17.0 (SPSS
Inc., Chicago, IL, USA). For all statistical analyses, pb0.05 was accepted
as being statistically signiﬁcant, with pb0.1 accepted as showing a
trend of change.
Results
Y1 receptor deletion is restricted to osteoblasts
The restriction of Y1 receptor deletion solely to osteoblastic cells of
Y1lox/lox;Cre/+ mice was conﬁrmed by RT-PCR for Cre and Y1 receptor
expression on RNA isolated from several tissues from Y1lox/lox
and Y1lox/lox;Cre/+ mice. As shown in Fig. 1, in Y1lox/lox;Cre/+ mice
which carry the Cre transgene, Cre mRNA expression was indeed
restricted to bone tissue and isolated BMSCs and was not observed in
other tissues examined namely brain, muscle or epididymal white
adipose tissue. No Cre mRNA expression was observed in any tissue
investigated from Y1lox/lox littermates. In addition, coincident with Cre
expression, Y1 receptor expressionwas down-regulated in bone tissue
and cultured BMSCs derived from Y1lox/lox;Cre/+ mice (Fig. 1). Indeed,
quantiﬁcation of multiple analyses by densitometry revealed a 95%
reduction in Y1 receptor expression in bone tissue from Y1lox/lox;Cre/+
mice compared to their wildtype littermates. Y1 receptor expression
was unaffected in other tissues examined, conﬁrming the generation
of mice with the Y1 receptor deleted solely in osteoblasts.
Osteoblast-speciﬁc Y1 receptor deletion enhances bone formation with
no effect on adiposity
In addition to high bone mass, germline Y1−/− mice are
characterised by increased adiposity and hyperinsulinemia, an obese
phenotype that is exacerbated with advancing age [3,16,17]. There-
fore, to examine whether osteoblast-speciﬁc deletion of the Y1
receptor could recapitulate the high bonemass phenotype of germline
Y1−/− mice independent of other metabolic changes, we ﬁrst
measured body composition by DXA in Y1lox/lox and Y1lox/lox;Cre/+
mice at 16 weeks of age, a similar age to that previously used for the
analysis of the bone phenotype in germline Y1−/− mice [3,10].
Importantly, no differences were observed between Y1lox/lox and
Y1lox/lox;Cre/+ mice with respect to body weight, whole body lean
tissue mass or fat mass (Table 1). Similar stature and adiposity
between Y1lox/lox;Cre/+ and Y1lox/lox mice was further conﬁrmed by a
lack of difference in femur length and the weight of individual white
adipose tissue depots (Table 1 and data not shown). In addition, we
found no signiﬁcant effect of genotype on serum concentrations of
insulin, glucose, corticosterone, or IGF-1 (Table 1). Importantly,
however, whole body DXA analysis revealed a trend towards
increased BMC and BMD in the Y1lox/lox;Cre mice compared to their
wildtype littermates with a signiﬁcant increase in BMC also evident at
the lumbar vertebrae (Table 1), consistent with a role for Y1 receptors
on osteoblasts in the inhibition of bone formation independently of
any effects on adiposity or hormones such as corticosterone or IGF-1.
Therefore, in order to further investigate the bone phenotype of these
mice, we measured cancellous and cortical bone parameters by
histomorphometry and micro computed tomography (micro-CT)
in distal femurs isolated from 16 week old Y1lox/lox;Cre/+ mice, as
compared to their Y1lox/lox littermates.
Cancellous bone
Histomorphometric analysis revealed that male Y1lox/lox;Cre/+mice
have signiﬁcantly greater (by 40%) cancellous bone volume in the
distal femoral metaphysis compared to their wildtype littermates
with signiﬁcantly greater trabecular thickness and trabecular number
(Fig. 2A–D). Similar to male germline Y1−/− mice [3], this was
associated with an increase in osteoblast activity as shown by
signiﬁcantly enhanced MAR (Fig. 2E) and bone formation rate
(Fig. 2F), without a change in the extent of bone undergoing bone
formation (mineralising surface (Fig. 2G)). However, in contrast to
germline Y1−/− mice, the activity of the osteoclastic lineage was
similar between Y1lox/lox;Cre/+ mice and their wildtype littermates in
that therewas no difference observed in osteoclast surface (Fig. 2H) or
osteoclast number (Fig. 2I). Therefore, the enhanced cancellous
bone volume observed in Y1lox/lox;Cre/+ mice is entirely associated
with enhanced bone formation with no change in bone resorption
parameters.
Cortical bone
Micro-CT was used to examine the effect of osteoblast-speciﬁc Y1
receptor deletion on cortical bone. At the mid-femur, Y1lox/lox;Cre/+
mice displayed a generalised increase in the diameter of the femur as
shown by signiﬁcant increases in total tissue area, marrow area,
periosteal perimeter and endosteal perimeter (Fig. 3A–D). Despite
Fig. 1. Osteoblast-speciﬁc Y1 receptor deletion. Y1 receptor knockdown and Cre
expression in bone tissue and BMSCs after 10 days in culture in osteogenicmedia but not
in brain, muscle or epididymal white adipose tissue (WATe) derived from Y1lox/lox;Cre/+
mice but not Y1lox/lox littermates. Data show results for PCR performed with (+) and
without (−) reverse transcription. PCRwas performed for 22–26 cycles for GAPDH, 32–
26 cycles for Y1 receptor, and 36–40 cycles for Cre varying between tissue types but
consistent across genotypes.
Table 1
Body composition, serum parameters and bone densitometry of Y1lox/lox;Cre/+ mice.
Y1lox/lox Y1lox/lox;Cre/+
Body weight (g) 26.47±0.50 26.77±0.66
Lean mass (g) 20.55±0.29 20.52±0.45
Fat mass (g) 4.70±0.29 4.54±0.27
Femur length (mm) 15.99±0.12 15.94±0.14
Insulin (pM) 136.24±29.88 165.90±35.97
Glucose (mM) 10.95±0.43 11.79±0.49
Corticosterone (ng/mL) 89.42±21.89 119.26±23.08
IGF-1 (ng/mL) 215.34±20.98 230.09±16.70
Whole body BMC (g) 0.322±0.006 0.341±0.009 c
Whole body BMD (g/cm2) 0.0500±0.0006 0.0519±0.0008 b
Lumbar BMC (g) 0.0285±0.0005 0.0315±0.0013 a
Lumbar BMD (g/cm2) 0.0513±0.0007 0.0528±0.0020
Means±SEM of 9–13 male mice per group shown.
a pb0.05.
b p=0.06.
c p=0.09 compared to Y1lox/lox mice.
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Fig. 2. Osteoblastic Y1 receptor deletion enhances cancellous bone mass and osteoblast activity. Histomorphometry reveals that Y1lox/lox;Cre/+ mice show signiﬁcantly greater
cancellous bone volume (BV/TV) (A), trabecular thickness (B), and trabecular number (C) than their Y1lox/lox littermates, in keeping with 3-dimensional reconstructions of the distal
femoral metaphysis (D). This increase is associated with signiﬁcantly increased MAR (E) and bone formation rate (F) with no change in mineralising surface (G), osteoclast surface
(H), or osteoclast number (I). Mean±SEM of 6–13 male mice per group are shown. *pb0.05, **pb0.01, ***pb0.001 compared to Y1lox/lox. Bar represents 0.2 mm (D).
Fig. 3. Osteoblastic Y1 receptor deletion enhances cortical bone size and osteoblast activity. Micro-CT reveals that Y1lox/lox;Cre/+ mice show greater total tissue area (A) at the mid-
femoral diaphysis than their Y1lox/lox littermates with increased marrow area (B), periosteal perimeter (C), and endosteal perimeter (D) with no change in cortical bone area (E) or
cortical thickness (F) as illustrated by representative 3-dimensional reconstructions (G). These changes are associated with increased mean polar moment of inertia (MPMI; H) and
increased MAR on the endocortical (I) and periosteal (J) surfaces. Mean±SEM of 6–13 male mice per group are shown. *pb0.05, **pb0.01, ***pb0.001 compared to Y1lox/lox. Bar
represents 0.2 mm (G).
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Mature osteoblastic markers are increased in the absence of osteoblastic Y1 receptors 
        To further analyse the functional role of Y1 receptors in mature osteoblastic cells, we 
isolated RNA from the long bones of Y1lox/lox;Cre/+ mice and their wildtype littermates and 
analysed the expression of key osteoblastic markers. Consistent with a direct role for Y1 
receptors in the differentiation of osteoprogenitor cells, it has previously been shown that the 
mRNA levels of two key osteogenic transcription factors, Runx2 and Osterix, are significantly 
upregulated in the bones of 7- to 9-week-old germline Y1−/− mice [7]. Interestingly, here we 
show no significant difference in the mRNA expression levels of either Runx2 or Osterix in the 
long bones of mice lacking Y1 receptors solely in mature osteoblasts at a similar age (Fig. 4), 
consistent with these transcription factors predominantly playing roles in early osteogenic 
differentiation. However, similar to germline Y1−/− mice [7] and in keeping with their high bone 
mass and anabolic phenotype, Y1lox/lox;Cre/+ mice show a trend towards an increase in alkaline 
phosphatase mRNA expression compared to their wildtype littermates (Fig. 4). Importantly, 
Y1lox/lox;Cre/+ mice also showed an upregulation in the mRNA expression levels of two mature 
osteoblastic markers, osteocalcin and dentin matrix protein (DMP)-1, compared to their 
wildtype controls, although this failed to reach significance in the case of osteocalcin 
(p = 0.08; Fig. 4). 
	  	  
 Finally, no difference was observed between Y1lox/lox;Cre/+ mice and their wildtype 
littermates in the mRNA expression levels of either RANK-ligand, OPG or the ratio of RANK-
ligand to OPG (Fig. 4). These data are consistent with the histomorphometric data shown 
above and indicate that osteoblastic Y1 receptor deletion does not directly affect osteoclast 
activity. 
 
Discussion 
 
The findings presented here show for the first time that Y1 receptors expressed directly on 
osteoblasts play a critical role in the regulation of bone mass in vivo. The specific deletion of 
osteoblastic Y1 receptors in mice was sufficient to alter both osteoblast activity and bone 
mass. Specifically, Y1lox/lox;Cre/+ mice showed increased cancellous bone volume, trabecular 
number and trabecular thickness in association with enhanced osteoblast activity as 
demonstrated by significantly increased MAR and bone formation rate despite no difference 
in mineralising surface. In addition, Y1lox/lox;Cre/+ mice displayed enhanced endocortical and 
periosteal MAR with a trend towards increased cortical bone strength, as estimated by polar 
moment of inertia, associated with increased femoral diameter. Importantly, the changes 
observed in the bones of these mice occurred without any change in body weight, white 
no signiﬁcant changes in cortical bone area or cortical thickness
(Fig. 3E–F), the greater femur size in Y1lox/lox;Cre/+ mice (Fig. 3G) was
associated with increased polar moment of inertia, an index of bone
strength (Fig. 3H).
To investigate the cellular basis for these differences, MAR on the
endocortical and periosteal surfaces were examined. Interestingly,
endocortical MAR was signiﬁcantly elevated by approximately 60%
in male Y1lox/lox;Cre/+ mice compared to their wildtype littermates
(Fig. 3I). Cortical osteoblast activity was also elevated on the
periosteal surface as shown by a signiﬁcant increase in periosteal
MAR in the absence of osteoblastic Y1 receptors (Fig. 3J).
Together these data demonstrate that speciﬁc deletion of
osteoblastic Y1 receptors enhances osteoblast activity leading to
increases in both cortical and cancellous bone mass, with no effect on
bone resorption, adiposity, circulating concentrations of the hor-
mones insulin, IGF-1 or corticosterone, or body weight.
Mature osteoblastic markers are increased in the absence of osteoblastic
Y1 receptors
To further analyse the functional role of Y1 receptors in mature
osteoblastic cells,we isolated RNA from the long bones of Y1lox/lox;Cre/+
mice and their wildtype littermates and analysed the expression
of key osteoblastic markers. Consistent with a direct role for Y1
receptors in the differentiation of osteoprogenitor cells, it has
previously been shown that the mRNA levels of two key osteogenic
transcription factors, Runx2 and Osterix, are signiﬁcantly upregulated
in the bones of 7- to 9-week-old germline Y1−/− mice [7].
Interestingly, here we show no signiﬁcant difference in the mRNA
expression levels of either Runx2 or Osterix in the long bones of mice
lacking Y1 receptors solely in mature osteoblasts at a similar age
(Fig. 4), consistent with these transcription factors predominantly
playing roles in early osteogenic differentiation. However, similar to
germline Y1−/− mice [7] and in keeping with their high bone mass
and anabolic phe type, Y1lox/lox;Cre/+ mice show a trend towards an
increase in alkaline phosphatase mRNA expression compared to th ir
wildtype littermates (Fig. 4). Importantly, Y1lox/lox;Cre/+ mice also
showed an upregulation in the mRNA expression levels of twomature
osteoblastic markers, osteocalcin and dentin matrix protein (DMP)-1,
compared to their wildtype controls, although this failed to reach
signiﬁcance in the case of osteocalcin (p=0.08; Fig. 4).
Finally, no difference was observed between Y1lox/lox;Cre/+ mice
and their wildtype littermates in the mRNA expr ssion leve s of either
RANK-ligand, OPG or the ratio of RANK-ligand to O G (Fig. 4). These
data are consistent with the histomorphometric data shown above
and indicate that osteoblastic Y1 receptor deletion does not directly
affect osteoclast activity.
Discussion
The ﬁndings presented here show for the ﬁrst time that Y1
receptors expressed directly on osteoblasts play a critical role in the
regulation of bonemass in vivo. The speciﬁc deletion of osteoblastic Y1
receptors in mice was sufﬁcient to alter both osteoblast activity and
bone mass. Speciﬁcally, Y1lox/lox;Cre/+ mice showed increased cancel-
lous bone volume, trabecular number and trabecular thickness in
association with enhanced osteoblast activity as demonstrated by
signiﬁcantly increased MAR and bone formation rate despite no
difference in mineralising surface. In addition, Y1lox/lox;Cre/+ mice
displayed enhanced endocortical and periosteal MAR with a trend
towards increased cortical bone strength, as estimated by polar
moment of inertia, associated with increased femoral diameter.
Importantly, the changes observed in the bones of these mice
occurred without any change in body weight, white adipose tissue
mass, or circulating IGF-1, corticosterone, glucose or insulin levels.
In keeping with the deletion of Y1 receptors being restricted
to mature osteoblasts, key markers of mature osteoblast activity,
alkaline phosphatase, osteocalcin and DMP-1, were all upregulated in
Y1lox/lox;Cre/+ mice with no change in the expression levels of
transcription factors predominantly involved early in osteogenic
differentiation, Runx2 and Osterix. Interestingly, these gene expres-
sion changes occur at a young age (7–9 weeks old) before an increase
in bone mass can be detected by DXA analysis (data not shown).
Taken together, these data suggest that osteoblastic Y1 receptors are
primarily responsible for the Y1-mediated regulation of bone.
Moreover, these data show that the NPY system can directly regulate
osteoblast activity via Y1 receptors in vivo.
The high bone mass phenotype of Y1lox/lox;Cre/+ mice shown here
is similar to that previously described for germline Y1−/− mice [3].
However, the magnitude of change in the bones of Y1lox/lox;Cre/+ mice
ompared to their wildtype controls was not as great as previously
observed in germline Y1−/− mice. Whilst germline Y1−/− mice
displayed a strong increase in cortical bone volume clearly evident by
DXA analysis [10], the increase in cortical bone in Y1lox/lox;Cre/+ mice
was more subtle. We have previously shown that the Y1 receptor
plays an inhibitory role in the differentiation of osteoblastic cells from
mesenchymal progenitor cells in vitro [7]. As Cre expression and
subsequent Y1 receptor deletion in the Y1lox/lox;Cre/+ mice used in this
study was restricted to mature osteoblasts, this suggests that
enhanced osteoblast differentiation due to lack of Y1 receptors on
less mature osteoblastic cells may also contribute to the high bone
mass phenotype of germline Y1−/− mice. This is supported by the
observation that the key transcription factors, Runx2 and Osterix,
which predominantly play roles early in osteogenic differentiation
are signiﬁcantly upregulated in germline Y1−/− mice [7] but not in
Y1lox/lox;Cre/+ mice where Y1 deletion is restricted to mature osteo-
blasts. Although not signiﬁcant, a slight increase in the expression
levels of Runx2 and Osterix was still observed in Y1lox/lox;Cre/+ mice,
reﬂecting the fact that these factors can also play a role inmoremature
osteoblasts [18,19]. Additionally, it is also possible that indirect effects
caused by the global deletion of the Y1 receptor, such as increased
adiposity and hyperinsulinemia, also contribute to the higher bone
mass phenotype of germline Y1−/−mice, due to–for example–greater
weight bearing effects to stimulate bone mass [20] and effects of
insulin to promote bone formation [21,22]. Importantly, herewe show
that without these potential compensatory factors, osteoblastic Y1
receptor deletion is sufﬁcient to enhance bone mass without affecting
body weight, adiposity or circulating hormone levels.
In addition to a generalised increase in bone formation, there is
also a suggestion of altered bone resorption in germline Y1−/−mice as
indicated by an increase in osteoclast surface [3]. Whether this is due
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Fig. 4. Alkaline phosphatase (ALP), osteocalcin (OSC) and dentin matrix protein (DMP)-
1 are up regulated in the absence of osteoblastic Y1 receptors. Quantitative real-time
PCR analysis shows an increase in mRNA levels of ALP, OSC and DMP-1 but not Runx2,
Osterix, RANK-ligand (RL), OPG or the RANK-ligand to OPG ratio (RL:OPG) in the long
bones of 7- to 9-week-old male Y1lox/lox;Cre/+ mice compared to those of their wildtype
littermates. Values shown are normalised to β-actin levels and relative to wildtype
expression. Data are means±SEM of 5–8 mice per genotype. *pb0.05 as indicated.
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adipose tissue mass, or circulating IGF-1, corticosterone, glucose or insulin levels. In keeping 
with the deletion of Y1 receptors being restricted to mature osteoblasts, key markers of 
mature osteoblast activity, alkaline phosphatase, osteocalcin and DMP-1, were all 
upregulated in Y1lox/lox;Cre/+ mice with no change in the expression levels of transcription 
factors predominantly involved early in osteogenic differentiation, Runx2 and Osterix. 
Interestingly, these gene expression changes occur at a young age (7–9 weeks old) before 
an increase in bone mass can be detected by DXA analysis (data not shown). Taken 
together, these data suggest that osteoblastic Y1 receptors are primarily responsible for the 
Y1-mediated regulation of bone. Moreover, these data show that the NPY system can directly 
regulate osteoblast activity via Y1 receptors in vivo. 
 The high bone mass phenotype of Y1lox/lox;Cre/+ mice shown here is similar to that 
previously described for germline Y1−/− mice [3]. However, the magnitude of change in the 
bones of Y1lox/lox;Cre/+ mice compared to their wildtype controls was not as great as previously 
observed in germline Y1−/− mice. Whilst germline Y1−/− mice displayed a strong increase in 
cortical bone volume clearly evident by DXA analysis [10], the increase in cortical bone in 
Y1lox/lox;Cre/+ mice was more subtle. We have previously shown that the Y1 receptor plays an 
inhibitory role in the differentiation of osteoblastic cells from mesenchymal progenitor cells in 
vitro [7]. As Cre expression and subsequent Y1 receptor deletion in the Y1lox/lox;Cre/+ mice used 
in this study was restricted to mature osteoblasts, this suggests that enhanced osteoblast 
differentiation due to lack of Y1 receptors on less mature osteoblastic cells may also 
contribute to the high bone mass phenotype of germline Y1−/− mice. This is supported by the 
observation that the key transcription factors, Runx2 and Osterix, which predominantly play 
roles early in osteogenic differentiation are significantly upregulated in germline Y1−/− mice [7] 
but not in Y1lox/lox;Cre/+ mice where Y1 deletion is restricted to mature osteoblasts. Although not 
significant, a slight increase in the expression levels of Runx2 and Osterix was still observed 
in Y1lox/lox;Cre/+ mice, reflecting the fact that these factors can also play a role in more mature 
osteoblasts [18] and [19]. Additionally, it is also possible that indirect effects caused by the 
global deletion of the Y1 receptor, such as increased adiposity and hyperinsulinemia, also 
contribute to the higher bone mass phenotype of germline Y1−/− mice, due to–for example–
greater weight bearing effects to stimulate bone mass [20] and effects of insulin to promote 
bone formation [21] and [22]. Importantly, here we show that without these potential 
compensatory factors, osteoblastic Y1 receptor deletion is sufficient to enhance bone mass 
without affecting body weight, adiposity or circulating hormone levels. 
 In addition to a generalised increase in bone formation, there is also a suggestion of 
altered bone resorption in germline Y1−/− mice as indicated by an increase in osteoclast 
surface [3]. Whether this is due to a lack of direct action of Y1 receptors on bone cells is 
currently unknown. It is possible that the increase in osteoclast surface observed in germline 
Y1−/− mice is due to altered osteoblastic signalling essential in the control of osteoclast 
recruitment and activity [23]. Previous in vitro studies have shown that NPY can indeed alter 
osteoclastogenesis by affecting the production of cAMP, RANK-ligand and OPG in mouse 
bone marrow cells [24] and [25]. Thus, alterations in osteoblast behaviour due to the lack of 
Y1 receptors may be responsible for a change in osteoclast activity seen in germline Y1−/− 
mice. However, here we have shown that the deletion of Y1 receptors solely in mature 
osteoblasts enhanced osteoblast activity and bone mass without affecting osteoclast surface, 
osteoclast number or the expression levels of RANK-ligand, OPG or the RANK-ligand to OPG 
ratio. Consistent with the marked decrease in RANK-ligand expression during osteoblast 
maturation [26], these data suggest that the elevated activity of the osteoclast lineage 
observed in germline Y1−/− mice is not due to altered signalling from mature osteoblasts. The 
stimulation of the osteoclastic lineage in germline Y1−/− mice may instead result from 
signalling from less mature cells of the osteoblastic lineage, a direct effect of the lack of Y1 
receptors on osteoclasts themselves or, as discussed above, an indirect effect caused by the 
global deletion of the Y1 receptor. Interestingly, it has been previously demonstrated that 
NPY signalling through the Y1 receptor plays a role in the normal function of macrophages, 
which, like osteoclasts, are derived from hematopoietic stem cells through the 
monocyte/macrophage lineage [27]. Therefore, it is conceivable that Y1 receptors are also 
expressed on osteoclasts where they can respond to NPY signalling and alter bone 
resorption, however further studies would be needed to support this hypothesis. 
 A peripheral, osteoblastic role for Y1 receptors in the regulation of bone is consistent 
with a growing understanding of the direct effects of neural signalling on bone cell activity. 
Adrenergic [28], glutamatergic [29] and cannabinoid [30] receptors are among those neural 
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signals recently described as directly mediating changes in bone homeostasis. NPY-
immunoreactive fibres [31], [32] and [33] and NPY protein [34] have been shown in bone 
tissue and it has also been shown that osteoblasts and osteocytes express NPY [11] and [12] 
as well as the Y1 receptor [10]. Therefore, osteoblastic Y1 receptors may be mediating the 
effects of NPY produced from central, local as well as other peripheral sources. 
 It should also be noted that the gut hormone peptide YY (PYY), another ligand of the 
NPY system, binds to the Y1 receptor with equal affinity to NPY [35]. PYY has also been 
shown to play a role in bone homeostasis and may be involved peripherally in the regulation 
of bone formation through osteoblastic Y1 receptors. Elevated PYY levels have been shown 
to correlate with diminished BMD in women with anorexia nervosa, a condition that results in 
significant bone loss [36]. However, analysis of a PYY knockout line found that a lack of PYY 
led to an osteopenic phenotype with reductions in vertebral cancellous bone mass and bone 
strength [37]. Clearly, further investigations are needed to delineate the underlying 
mechanisms in the control of bone mass by PYY and to determine whether PYY regulates 
bone mass via central and/or peripheral pathways. 
 This novel model investigated in this study has enabled us to demonstrate a key role 
for osteoblastic Y1 receptors in the control of bone homeostasis. The results described here 
show that osteoblast activity was enhanced in the absence of osteoblastic Y1 receptors in 
male mice. This was sufficient to alter cancellous and cortical bone mass generating a bone 
phenotype similar to that of germline Y1−/− mice without the hyperinsulinemia and obesity 
associated with generalised Y1 receptor deficiency. Therefore, these data suggest that 
osteoblastic Y1 receptors may be a potentially important target for the development of 
therapeutic approaches to osteoporosis. 
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